Allometric scaling is one of the tools that drug developers use to predict human PK based upon animal data. Prediction methods, like allometric scaling, provide a “sneak peek” at how a drug might behave in humans before any clinical studies are conducted.
This webinar covers an introduction of allometric scaling as well as extrapolation from animals to humans for predicting pharmacokinetic (PK) data and dose selection. At the end of this webinar attendees should have a better understanding of:
- Allometry and the nature of allometric exponents
- Dose projection based on the predicted PK parameters in humans
- Appropriate application of the allometric exponents to improve the prediction of PK parameters in humans from animal PK
Meet the Speaker
Iftekhar Mahmood, Ph.D.
Senior Consultant, Clinical Pharmacology and Pharmacometrics
Dr. Mahmood has more than 25 years of experience in clinical pharmacology with the FDA. He worked both in the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER). At the FDA, besides his review duties, Dr. Mahmood was involved with clinical pharmacology research (both small and large molecules) and published more than 100 research papers in peer-reviewed scientific journals. His research mainly focused on allometric scaling, modeling, sparse sampling, and pediatric drug development.